Notice of Interim Results and Investor Presentation

Monday August 22, 2022

Destiny Pharma plc
(“Destiny Pharma” or the “Company”)

Notice of Interim Results and Investor Presentation

Brighton, United Kingdom ‐ 22 August 2022 ‐ Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life‐threatening infections, will announce its interim results for the period ended 30th June 2022, on Thursday 8th September 2022.

Neil Clark, Chief Executive Officer and Shaun Claydon, Chief Financial Officer, will provide a live presentation on the same day, at 10:00 am BST, followed by a Q&A session accessible via the Investor Meet Company platform. The webcast of the presentation will be available on the Company’s investor relations website at

The presentation is open to analysts and all existing and potential new shareholders. Questions can be submitted pre-event via the Investor Meet Company Dashboard up until 09:00 am BST the day before the meeting, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free, and add to meet Destiny Pharma plc via:‐pharma‐plc/register‐investor

Investors who already follow Destiny Pharma plc on the Investor Meet Company platform will automatically be invited.

For further information please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440

Optimum Strategic Communications
Mary Clark / Manel Mateus / Eleanor Cooper
+44 (0) 203 922 0891

finnCap Ltd (Nominated Advisor and Broker)
Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500

MC Services AG
Anne Hennecke / Andreas Burckhardt

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life‐threatening infections. Its pipeline has novel microbiome‐based biotherapeutics and XF drug clinical assets including NTCD‐M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF‐73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post‐surgical staphylococcal hospital infections including MRSA. It is also co‐developing SPOR‐COVTM, a novel, biotherapeutic product for the prevention of COVID‐19 and other viral respiratory infections and has earlier grant funded XF drug research projects.

For further information on the company, please visit